AKT1 and breast carcinoma: Activation of the PI3K-Akt-mTOR pathway may trigger endocrine resistance to tamoxifen and fluvestrant in breast cancer, while miR-214 could increase the sensitivity of breast cancer cells to 4-OHT/FUL through inhibition of autophagy via the PI3K-Akt-mTOR pathway [44].